Current:Home > ContactHow well does a new Alzheimer's drug work for those most at risk? -MoneyMatrix
How well does a new Alzheimer's drug work for those most at risk?
View
Date:2025-04-13 07:24:30
Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people.
While some saw it as undeniable progress for a disease with no other proven treatment, others urged caution because of severe side effects and the finding of only a "modest" effect. Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School, has another concern: the racial and ethnic makeup of the trial.
The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it still was not enough to definitively say if the drug is effective for Black people.
"[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," Jackson, director of the Community Access, Recruitment, and Engagement Research Center, says.
The makers of lecanemab say the trial was able to enroll more Black and Hispanic patients by removing some of the requirements that had been in place for previous trials. They cite tapping into community outreach groups and making it "easy for the patients to enroll into the study, and we made it easy for the patients to actually continue to participate in the study," says Shobha Dhadda, Vice President of Biostatistics and clinical development operations for Neurology at the pharmaceutical company Esai.
The trial enrollment comes close to reaching the racial breakdown of people 65 and older according to the census, but Jackson says that's the wrong goal. Black and Hispanic people, women, and those with a genetic predisposition are all at disproportionately high risk for developing Alzheimer's. Jackson says companies should be overrepresenting these groups in their trials.
"If we continue to study privileged populations ... we're leaving huge questions unanswered about how Alzheimer's works, how it progresses, and what are the significant risk factors," he says. "So when you're designing a study, you should really worry less about the census and more about trying to represent those who are disproportionately affected."
On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.
Have suggestions for what we should cover in future episodes? Email us at [email protected].
This episode was produced by Liz Metzger and edited by Gabriel Spitzer. Anil Oza contributed additional reporting and checked the facts. Patrick Murray was the audio engineer.
veryGood! (22)
Related
- Alex Murdaugh’s murder appeal cites biased clerk and prejudicial evidence
- What were Tom Selleck's juicy final 'Blue Bloods' words in Reagan family
- A South Texas lawmaker’s 15
- Paris Hilton, Nicole Richie return for an 'Encore,' reminisce about 'The Simple Life'
- Paula Abdul settles lawsuit with former 'So You Think You Can Dance' co
- 'No Good Deed': Who's the killer in the Netflix comedy? And will there be a Season 2?
- Head of the Federal Aviation Administration to resign, allowing Trump to pick his successor
- Head of the Federal Aviation Administration to resign, allowing Trump to pick his successor
- Why Sean "Diddy" Combs Is Being Given a Laptop in Jail Amid Witness Intimidation Fears
- Whoopi Goldberg is delightfully vile as Miss Hannigan in ‘Annie’ stage return
Ranking
- Will the 'Yellowstone' finale be the last episode? What we know about Season 6, spinoffs
- Federal court filings allege official committed perjury in lawsuit tied to Louisiana grain terminal
- John Galliano out at Maison Margiela, capping year of fashion designer musical chairs
- Opinion: Gianni Infantino, FIFA sell souls and 2034 World Cup for Saudi Arabia's billions
- Rams vs. 49ers highlights: LA wins rainy defensive struggle in key divisional game
- Selena Gomez's "Weird Uncles" Steve Martin and Martin Short React to Her Engagement
- Sonya Massey's father decries possible release of former deputy charged with her death
- Google unveils a quantum chip. Could it help unlock the universe's deepest secrets?
Recommendation
Meet the volunteers risking their lives to deliver Christmas gifts to children in Haiti
Macy's says employee who allegedly hid $150 million in expenses had no major 'impact'
Where will Elmo go? HBO moves away from 'Sesame Street'
DoorDash steps up driver ID checks after traffic safety complaints
Are Instagram, Facebook and WhatsApp down? Meta says most issues resolved after outages
Juan Soto to be introduced by Mets at Citi Field after striking record $765 million, 15
'Most Whopper
What do we know about the mysterious drones reported flying over New Jersey?